TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12001556

Group type: EXPERIMENTAL
Intervention: Activator MAA
Number of subjects: 26

Group type: COMPARATOR
Intervention: Silencor MAA
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both appliances
Number of subjects: 26
Study: 29754836

Group type: EXPERIMENTAL
Intervention: Misoprostol 200 μg oral, four times daily for 8 weeks
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 104
Study: 27335011

Group type: COMPARATOR
Intervention: Tracer group (1 ml carbon nanoparticle suspension)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Drug-load group (3 ml carbon nanoparticle-epirubicin suspension)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Control group (no lymphatic tracers)
Number of subjects: 90
Study: 24744384

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (ExT) in MetS subjects
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (ExT) in healthy control subjects
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (inactive) in MetS subjects
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (inactive) in healthy control subjects
Number of subjects: 22
Study: 23302708

Group type: EXPERIMENTAL
Intervention: Dynamic VR environment (Group D)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Dynamic and static VR training (Group D1)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Static VR environment (Group S)
Number of subjects: 16
Study: 20938962

Group type: EXPERIMENTAL
Intervention: Mixed adenotonsillectomy (electrocautery tonsillectomy with curettage adenoidectomy)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Cold adenotonsillectomy
Number of subjects: 72
Study: 18825579

Group type: EXPERIMENTAL
Intervention: Arthritis Self-Management Programme (ASMP) with added exercise component
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 95
Study: 16321199

Group type: EXPERIMENTAL
Intervention: Conventional open craniotomy (COC)
Number of subjects: 2464

Group type: EXPERIMENTAL
Intervention: Computed‐tomography guided aspiration (CTGA)
Number of subjects: 2464

Group type: EXPERIMENTAL
Intervention: Key‐hole approach (KHA)
Number of subjects: 2464
Study: 12000204

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day
Number of subjects: 245

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245
Study: 10441920

Group type: EXPERIMENTAL
Intervention: 15-session prevention program teaching social resistance skills
Number of subjects: 2209

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2209
Study: 7874093

Group type: EXPERIMENTAL
Intervention: Patients with PCS
Number of subjects: 33

Group type: COMPARATOR
Intervention: Patients with MHI without PCS
Number of subjects: 33

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 33
Study: 2116532

Group type: EXPERIMENTAL
Intervention: Indirect calorimetry (IC)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Curreri formula (CURR)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Lower calorie:nitrogen ratio
Number of subjects: 49
Study: 708150

Group type: EXPERIMENTAL
Intervention: GOBA 1.0 g
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: GOBA 2.0 g
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg (D)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Alcohol 0.5 g/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: GOBA 1.0 g + Alcohol 0.5 g/kg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 24
Study: 30784635

Group type: EXPERIMENTAL
Intervention: CRADLE Vital Sign Alert intervention
Number of subjects: 536223
Study: 28206806

Group type: EXPERIMENTAL
Intervention: Parent training intervention led by military-connected facilitators
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parent training intervention led by civilian facilitators
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parent training intervention (both groups)
Number of subjects: 0
Study: 26035319

Group type: EXPERIMENTAL
Intervention: HBV monotherapy with either lamivudine or emtricitabine, N=56
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: HBV dual therapy with tenofovir disoproxil fumarate (TDF) + lamivudine or emtricitabine, N=59
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: HBV dual therapy
Number of subjects: 115
Study: 23930028

Group type: EXPERIMENTAL
Intervention: Fast pranayama (Group 1) - Kapalabhati, Bhastrika, Kukkuriya Pranayama
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Slow pranayama (Group 2) - Nadishodhana, Savitri, Pranav Pranayama
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (Group 3)
Number of subjects: 90
Study: 21774826

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP) given once a day for three days
Number of subjects: 384

Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL) given twice a day for three days
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 384

Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 384
Study: 19723787

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Combination of fluoxetine and CBT
Number of subjects: 327

Group type: COMPARATOR
Intervention: No treatment during follow-up (naturalistic follow-up)
Number of subjects: 327
Study: 16698862

Group type: EXPERIMENTAL
Intervention: Acetaminophen 1 g
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg + Acetaminophen 1 g
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 14507834

Group type: EXPERIMENTAL
Intervention: Recombinant hCG
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Recombinant LH
Number of subjects: 73

Group type: COMPARATOR
Intervention: Individually tailored IVM treatments (control group)
Number of subjects: 73
Study: 10775962

Group type: EXPERIMENTAL
Intervention: Nicardipine (intravenously 5 mg/hour for one week)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 8829017

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg QD, titrated to losartan/HCTZ 50 mg/12.5 mg QD after 4 weeks, then to 50 mg/25 mg QD after 8 weeks)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Nifedipine GITS (30 mg QD, titrated to 60 mg QD after 4 weeks, then to 90 mg QD after 8 weeks)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 223
Study: 1331482

Group type: EXPERIMENTAL
Intervention: High-dose carboplatin and etoposide with autologous bone marrow transplantation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High-dose carboplatin and etoposide with autologous bone marrow transplantation plus oxazaphosphorine (usually cyclophosphamide)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Carboplatin and etoposide alone
Number of subjects: 40
Study: 3858229

Group type: EXPERIMENTAL
Intervention: Xylitol-containing dentifrice (10% xylitol) with conventional treatment
Number of subjects: 990

Group type: EXPERIMENTAL
Intervention: Fluoride systemic administration (in milk or drinking water) with conventional treatment
Number of subjects: 990

Group type: COMPARATOR
Intervention: Conventional dental treatment procedures alone (fluoride-free dentifrices)
Number of subjects: 990
Study: 31122994

Group type: EXPERIMENTAL
Intervention: 12-week computerised cognitive training programme (five × 30 min sessions per week)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 60
Study: 29510970

Group type: EXPERIMENTAL
Intervention: Thought Spot platform (eHealth intervention)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Participatory design research (PDR) methods
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Workshops for feedback on platform usability
Number of subjects: 41
Study: 25950679

Group type: EXPERIMENTAL
Intervention: Dolder bar attachments
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Locator attachments
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Original dentures with Dolder bar
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Original dentures with Locator
Number of subjects: 46
Study: 25088638

Group type: EXPERIMENTAL
Intervention: Mechanical compression of the lid margin (Group A)
Number of subjects: 306

Group type: COMPARATOR
Intervention: No lid scrubbing (Group B)
Number of subjects: 306
Study: 22473250

Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Caloric restriction + Resistance training (CR + RT)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control
Number of subjects: 38
Study: 20148604

Group type: EXPERIMENTAL
Intervention: Comprehensive diabetes disease management program (DDMP) plus usual care
Number of subjects: 217

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 217
Study: 17200478

Group type: EXPERIMENTAL
Intervention: Risk factors for falls assessment
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: History of falls in the past year
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Assessment of gait or balance abnormalities
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Visual impairment, medication variables, decreased activities of daily living, impaired cognition
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Orthostatic hypotension
Number of subjects: 18
Study: 16036001

Group type: EXPERIMENTAL
Intervention: Telemedicine intervention using internet videoconferencing at 128 kbit/s
Number of subjects: 12
Study: 12131252

Group type: EXPERIMENTAL
Intervention: Amino acid provision (L‐lysine, L‐leucine, L‐valine, L‐phenylalanine, L‐threonine, L‐histidine, L‐isoleucine, and L‐methionine) with carbohydrates (dextrose, sucrose, and fructose) during a 12‐wk progressive knee extensor resistance training (PRT) program
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (no amino acid provision) during a 12‐wk progressive knee extensor resistance training (PRT) program
Number of subjects: 17
Study: 10386022

Group type: EXPERIMENTAL
Intervention: PVP-I nasal inhalation and gargling (1% PVP-I solution, 2 times/day for 2 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (gargling with PVP-I solution, 2 times/day for 2 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PVP-I nasal inhalation (1% PVP-I solution, 2 times/day for 2 weeks) without chronic respiratory complications
Number of subjects: 30
Study: 8767947

Group type: EXPERIMENTAL
Intervention: Endoscopic decompression
Number of subjects: 45

Group type: COMPARATOR
Intervention: Open decompression
Number of subjects: 45
Study: 1984743

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg once a day) + Pancrease (four capsules three times a day)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Pancrease (two capsules three times a day)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Pancrease (four capsules three times a day)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Pancrease (two capsules three times a day) + Omeprazole
Number of subjects: 9
Study: 6669627

Group type: EXPERIMENTAL
Intervention: 7.5 mg zopiclone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2 mg flunitrazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5 mg nitrazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30609439

Group type: EXPERIMENTAL
Intervention: TG-C (TissueGene-C) at a dose of 3.0 × 10^7 cells
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 30666962

Group type: EXPERIMENTAL
Intervention: Fractional flow reserve-guided complete revascularisation (FFR-CRV)
Number of subjects: 627

Group type: COMPARATOR
Intervention: Infarct-related artery only (IRA only)
Number of subjects: 627
Study: 26310513

Group type: EXPERIMENTAL
Intervention: EPO mouthwash (50 IU/ml, 15 ml four times a day)
Number of subjects: 80
Study: 26254056

Group type: EXPERIMENTAL
Intervention: Anti-TNFα therapy
Number of subjects: 915

Group type: COMPARATOR
Intervention: Ileostomy
Number of subjects: 915

Group type: COMPARATOR
Intervention: Pouch
Number of subjects: 915
Study: 24350571

Group type: EXPERIMENTAL
Intervention: Incredible Years Basic Parenting Programme
Number of subjects: 119

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 119
Study: 21422117

Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted influenza H1N1/A/09 vaccine (2 doses)
Number of subjects: 65

Group type: COMPARATOR
Intervention: AS03-adjuvanted influenza H1N1/A/09 vaccine (1 dose)
Number of subjects: 65
Study: 18512789

Group type: EXPERIMENTAL
Intervention: Strontium ranelate (2 gm/day)
Number of subjects: 5091

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5091
Study: 16598442

Group type: EXPERIMENTAL
Intervention: nCPAP treatment in hypertensive OSAS patients
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: nCPAP treatment in normotensive OSAS patients
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (normotensive patients without OSAS)
Number of subjects: 69
Study: 15381595

Group type: EXPERIMENTAL
Intervention: 5-day course of intravenous amoxicillin‐clavulanic acid
Number of subjects: 73

Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 73
Study: 10703931

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment (2 IU/m2/day = 0.67 mg/m2/day)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 29
Study: 9077617

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study: 8397723

Group type: EXPERIMENTAL
Intervention: L-dihydroxy-phenylalanine/carbidopa (100 mg/25 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 3535601

Group type: EXPERIMENTAL
Intervention: Intravenous heparin therapy
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study: 3389320

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (100 micrograms Se/d for 60 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Selenium supplementation
Number of subjects: 16
Study: 28977406

Group type: EXPERIMENTAL
Intervention: Modified reverse subclavian flap angioplasty (MRA), n=27
Number of subjects: 54

Group type: COMPARATOR
Intervention: Extended end‐to‐end anastomosis (EEA), n=27
Number of subjects: 54
Study: 28351093

Group type: EXPERIMENTAL
Intervention: Dietary weight reduction intervention
Number of subjects: 97

Group type: COMPARATOR
Intervention: Baseline Angiopoietin‐like protein 8/betatrophin
Number of subjects: 97

Group type: COMPARATOR
Intervention: Circulating ANGPTL8/betatrophin
Number of subjects: 97
Study: 25764613

Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shock wave therapy (rESWT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ultrasound therapy (US)
Number of subjects: 30
Study: 23791215

Group type: EXPERIMENTAL
Intervention: Holmium laser ablation of the prostate (HOLAP)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Photoselective vaporization of the prostate (PVP)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Both HOLAP and PVP
Number of subjects: 109

Group type: COMPARATOR
Intervention: PVP
Number of subjects: 109
Study: 20605590

Group type: COMPARATOR
Intervention: Laparoscopic VIH
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Open VIH
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Open surgical technique
Number of subjects: 145
Study: 18222251

Group type: EXPERIMENTAL
Intervention: On-pump CABG
Number of subjects: 3014

Group type: COMPARATOR
Intervention: Off-pump CABG
Number of subjects: 3014
Study: 17076224

Group type: EXPERIMENTAL
Intervention: Betaxolol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bisoprolol
Number of subjects: 40
Study: 14722683

Group type: EXPERIMENTAL
Intervention: LSO-PS (lutetium oxyorthosilicate/sodium iodide dual-head coincidence camera)
Number of subjects: 24

Group type: COMPARATOR
Intervention: BGO-PET (gold standard)
Number of subjects: 24
Study: 11770190

Group type: EXPERIMENTAL
Intervention: Climodien (estradiol valerate 2 mg plus dienogest 2 mg)
Number of subjects: 1501
Study: 9283792

Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: COMPARATOR
Intervention: Acarbose
Number of subjects: 16
Study: 20058464

Group type: EXPERIMENTAL
Intervention: Intraoperative indwelling urethral catheter (IUC)
Number of subjects: 32

Group type: COMPARATOR
Intervention: No intraoperative catheter (NC)
Number of subjects: 32
Study: 2941206

Group type: EXPERIMENTAL
Intervention: Prazosin (2 or 4 mg/day)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ketanserin (40 or 80 mg/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 15
Study: 31634724

Group type: EXPERIMENTAL
Intervention: Narrating/processing positive memories
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Writing/processing positive memories
Number of subjects: 65

Group type: COMPARATOR
Intervention: Time-matched control
Number of subjects: 65
Study: 29506970

Group type: EXPERIMENTAL
Intervention: Creatine Monohydrate 10 g daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Creatine Monohydrate 15 g daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Creatine Monohydrate (10 g or 15 g)
Number of subjects: 0
Study: 27437723

Group type: EXPERIMENTAL
Intervention: Mirror Therapy (MT group, n=9), therapy with a mirror box 5 days/week, 30 min/day, for 3 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Electromyography-triggered neuromuscular stimulation (ES group, n=7), therapy of similar duration and frequency as MT group
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional physiotherapy (Control group, n=8)
Number of subjects: 24
Study: 25493602

Group type: EXPERIMENTAL
Intervention: PrEP (daily oral tenofovir and emtricitabine/tenofovir) among women using DMPA
Number of subjects: 4747

Group type: COMPARATOR
Intervention: PrEP (daily oral tenofovir and emtricitabine/tenofovir) among women using no hormonal contraception
Number of subjects: 4747

Group type: EXPERIMENTAL
Intervention: PrEP (daily oral tenofovir and emtricitabine/tenofovir) among men whose partners used DMPA
Number of subjects: 4747

Group type: COMPARATOR
Intervention: PrEP (daily oral tenofovir and emtricitabine/tenofovir) among men whose partners used no hormonal contraception
Number of subjects: 4747
Study: 23046807

Group type: EXPERIMENTAL
Intervention: Brief counseling session to reduce alcohol risk
Number of subjects: 0

Group type: COMPARATOR
Intervention: Health education leaflet
Number of subjects: 0
Study: 20657780

Group type: EXPERIMENTAL
Intervention: Japanese young adults
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chinese young adults
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Asian-Canadian young adults
Number of subjects: 0
Study: 17854972

Group type: EXPERIMENTAL
Intervention: Instructor assessment of ventilation skills
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Instructor assessment of compressions
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Instructor assessment of compression depth
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Instructor assessment of hand placement
Number of subjects: 826
Study: 15994719

Group type: EXPERIMENTAL
Intervention: Quetiapine 600 mg/day
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Quetiapine 300 mg/day
Number of subjects: 542

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 542
Study: 12354427

Group type: EXPERIMENTAL
Intervention: Methionine-induced hyperhomocysteinemia
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: l-NMMA (0.3 mg/kg/min intravenously)
Number of subjects: 18
Study: 11092491

Group type: EXPERIMENTAL
Intervention: Low-field MR imaging with contrast enhancement (0.1 or 0.3 mmol/kg b.w. gadodiamide)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Clinical staging according to FIGO recommendations (1988)
Number of subjects: 95
Study: 9488190

Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (CCBs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: International Nifedipine Trial of Antiatherosclerotic Therapy (INTACT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Montreal Nicardipine Trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multicenter Isradipine/Diuretic Atherosclerosis Study (MIDAS)
Number of subjects: 0
Study: 8417552

Group type: EXPERIMENTAL
Intervention: 2-hour dawn simulation peaking at 250 lux
Number of subjects: 22

Group type: COMPARATOR
Intervention: 30-minute dawn simulation peaking at 0.2 lux
Number of subjects: 22
Study: 3508629

Group type: EXPERIMENTAL
Intervention: cimetidine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ranitidine
Number of subjects: 12

Group type: COMPARATOR
Intervention: misoprostol
Number of subjects: 12

Group type: COMPARATOR
Intervention: carbenoxolone
Number of subjects: 12
Study: 30691421

Group type: EXPERIMENTAL
Intervention: ZemCAD intervention
Number of subjects: 141

Group type: COMPARATOR
Intervention: Current care as usual (CAU)
Number of subjects: 141
Study: 29045323

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention
Number of subjects: 1341

Group type: COMPARATOR
Intervention: Health Education (HE) program
Number of subjects: 1341
Study: 25902885

Group type: EXPERIMENTAL
Intervention: Combination therapy (rosuvastatin 5 mg/day + ezetimibe 10 mg/day)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Monotherapy (rosuvastatin 5 mg/day)
Number of subjects: 51
Study: 23597420

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 583

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 583
Study: 21718124

Group type: EXPERIMENTAL
Intervention: Mental Health First Aid (MHFA) training, 12 hours duration
Number of subjects: 272
Study: 19700099

Group type: EXPERIMENTAL
Intervention: Primary paclitaxel‐eluting stent implantation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Primary percutaneous transluminal angioplasty (PTA)
Number of subjects: 0